Back to Market返回行情

CLPT ClearPoint Neuro, Inc.

USHealthcare
$17.50-2.13%ClosedMarket Cap: $524.8M

As of 2026-07-10 16:00

Why CLPT matters now

ClearPoint Neuro, Inc. (CLPT) is a US stock in Healthcare. The latest InvestLog snapshot shows $17.50 with -2.13% on the session and $524.8M in market capitalization; recent performance reads 1-month +59.09% and YTD +29.90%.

The latest financial table shown here is Q1 2026, with revenue of $12.1M, net income of $-9.6M, and EPS of $-0.32. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -5.0%.

The latest indexable market news headline is "ClearPoint Neuro: AMT-130's FDA Reversal Revives The Bull Case" from Seeking Alpha.

Additional event context on this page matters because analyst consensus is Buy with a median target of $16.00; recent insider activity includes Richards Timothy T. filing M-Exempt. These signals are research inputs, not a recommendation.

Valuation

P/E (TTM)

PEG

P/B

27.87

P/S

13.12

EV/EBITDA

-23.71

DCF Value

$-11.99

FCF Yield

-5.0%

Div Yield

0.0%

Margins & Returns

Gross Margin

61.8%

Operating Margin

-65.2%

Net Margin

-71.6%

ROE

-141.0%

ROA

-31.1%

ROIC

-31.5%

Financials

PeriodRevenueNet IncomeEPS
Q1 2026$12.1M$-9.6M$-0.32
Q4 2025$10.4M$-7.8M$-0.27
FY 2025$37.0M$-25.5M$-0.90
Q3 2025$8.9M$-5.9M$-0.21

Analyst Ratings

Consensus

Buy

Target (Consensus)

$16.00

Target (Median)

$16.00

Target Range

$16.00 - $16.00

Strong Buy: 0Buy: 3Hold: 0Sell: 0Strong Sell: 0
B. Riley SecuritiesBuy
2026-06-18
B. Riley SecuritiesBuy
2026-03-18
StifelBuy
2025-08-01

Trading Activity

Insider Trades

Richards Timothy T.director
Sell2026-06-08
Richards Timothy T.director
Sell2026-06-08
Richards Timothy T.director
Sell2026-06-08
Richards Timothy T.director
Sell2026-06-02
JOHNSON B KRISTINEdirector
Sell2026-05-26

Company Info

Sector

Healthcare

Industry

Medical - Devices

Country

US

Exchange

Beta

1.31

ClearPoint Neuro, Inc. is a medical technology firm primarily operating within the United States. The company specializes in developing and commercializing sophisticated systems that facilitate minimally invasive brain surgeries, guided by real-time magnetic resonance imaging (MRI) during the procedure. Among its core offerings is the ClearPoint system, designed for the precise placement of deep brain stimulation electrodes, biopsy needles, and for the controlled infusion of medications and laser catheters directly into the brain. It also provides the ClearPoint Neuro Navigation System, which is specifically engineered for MRI suite environments. ClearPoint Neuro maintains strategic partnerships and licensing agreements with prominent institutions and companies, including Boston Scientific Corporation, The Johns Hopkins University, Clinical Laserthermia Systems Americas Inc, Koninklijke Philips N.V., Blackrock Neurotech, and the University of California, San Francisco. Initially established in 1998 and headquartered in Solana Beach, California, the company operated as MRI Interventions, Inc. before rebranding to ClearPoint Neuro, Inc. in February 2020.